Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious method, conolidine modulates alternate molecular targets. A Science Improvements study found that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7,